<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1320f–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1320f–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1320f–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1320f_1"><akn:num>1320f–1</akn:num><akn:heading>Selection of negotiation-eligible drugs as selected drugs</akn:heading><akn:content><akn:p>§ 1320f–1. Selection of negotiation-eligible drugs as selected drugs(a) In generalNot later than the selected drug publication date with respect to an initial price applicability year, in accordance with subsection (b), the Secretary shall select and publish a list of—(1) with respect to the initial price applicability year 2026, 10 negotiation-eligible drugs described in subparagraph (A) of subsection (d)(1), but not subparagraph (B) of such subsection, with respect to such year (or, all (if such number is less than 10) such negotiation-eligible drugs with respect to such year);

(2) with respect to the initial price applicability year 2027, 15 negotiation-eligible drugs described in subparagraph (A) of subsection (d)(1), but not subparagraph (B) of such subsection, with respect to such year (or, all (if such number is less than 15) such negotiation-eligible drugs with respect to such year);

(3) with respect to the initial price applicability year 2028, 15 negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1) with respect to such year (or, all (if such number is less than 15) such negotiation-eligible drugs with respect to such year); and

(4) with respect to the initial price applicability year 2029 or a subsequent year, 20 negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1), with respect to such year (or, all (if such number is less than 20) such negotiation-eligible drugs with respect to such year).


Subject to subsection (c)(2) and section 1320f–3(f)(5) of this title, each drug published on the list pursuant to the previous sentence and subsection (b)(3) shall be subject to the negotiation process under section 1320f–3 of this title for the negotiation period with respect to such initial price applicability year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period).

(b) Selection of drugs(1) In generalIn carrying</akn:p></akn:content><akn:subsection eId="subsec_1320f_1_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general Not later than the selected drug publication date with respect to an initial price applicability year, in accordance with subsection (b), the Secretary shall select and publish a list of— Subject to subsection (c)(2) and section 1320f–3(f)(5) of this title, each drug published on the list pursuant to the previous sentence and subsection (b)(3) shall be subject to the negotiation process under section 1320f–3 of this title for the negotiation period with respect to such initial price applicability year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_1_b"><akn:num>(b)</akn:num><akn:heading>Selection of drugs</akn:heading><akn:content><akn:p>(b) Selection of drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_1_c"><akn:num>(c)</akn:num><akn:heading>Selected drug</akn:heading><akn:content><akn:p>(c) Selected drug</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_1_d"><akn:num>(d)</akn:num><akn:heading>Negotiation-eligible drug</akn:heading><akn:content><akn:p>(d) Negotiation-eligible drug</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_1_e"><akn:num>(e)</akn:num><akn:heading>Qualifying single source drug</akn:heading><akn:content><akn:p>(e) Qualifying single source drug</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_1_f"><akn:num>(f)</akn:num><akn:heading>Special rule to delay selection and negotiation of biologics for biosimilar market entry</akn:heading><akn:content><akn:p>(f) Special rule to delay selection and negotiation of biologics for biosimilar market entry</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>